On August 10, 2018, AbbVie, Inc. and AbbVie Biotechnology Ltd. (collectively “AbbVie”) sued Sandoz Inc., Sandoz GMBH, and Sandoz...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK]
PTAB
-
-
The PTAB recently instituted a second IPR of US Patent 9,296,821 (“the ’821 patent”), which covers certain uses of Rituxan®...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
U.S. Patent No. 8,329,172 (“the ’172 patent”), a Biogen-owned patent covering a treatment regime for low-grade B-cell non-Hodgkin’s...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
The Patent Trial and Appeal Board (“PTAB”) recently denied Sandoz’s petition for inter partes review (“IPR”) of claims 1-30 of...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
Earlier this month, Celltrion, Inc. (“Celltrion”) filed a copycat IPR petition directed against U.S. Patent No. 7,976,838 (“the ʼ838...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
Earlier this month, the Patent Trial and Appeal Board (“PTAB” or “the Board”) denied institution of Sandoz’s petition for inter...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
The Patent Trial and Appeal Board (“the Board”) has decided not to institute inter partes review (“IPR”) on two patents owned by...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
On the same day that the PTAB instituted review of an AbbVie Biotechnology Ltd. (“AbbVie”) patent covering a method of using adalimumab...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
At the urging of Sandoz Inc. (“Sandoz”), the PTAB instituted review of claims 1, 2, and 5-7 of U.S. Patent No. 9,067,992 (“the ʼ992...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK]